Global Gene and Cell Therapy (GCT) Market – Analysis By Vector, Application, By Region, By Country (2021 Edition): Market Insights, Pipeline, Forecast with Impact of COVID-19 (2021-2026)
DESCRIPTION
TABLE OF CONTENTS
RELATED REPORTS
SAMPLE REQUEST
REVIEWS
DESCRIPTION
Executive Summary
The Global Gene and Cell Therapy (GCT) Market is estimated at USD 2504.2 Million in the year 2020. Growth in the historic period in the cell and gene therapy market resulted from increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical R&D expenditure.
Companies in the gene and cell therapy for oncology market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, organizations are developing innovative products as well as sharing skills and expertise with other such enterprises. While oncology drug companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years.
Further, the market was restrained by inadequate reimbursements, challenges due to regulatory changes, low healthcare access, and limited number of treatment centers. Going forward, increasing prevalence of cancer and chronic diseases, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure will drive the growth in the gene and cell therapy market. Factors that could hinder the growth of the market in the future include high costs of therapy, stringent regulations, reimbursement challenges, and coronavirus pandemic.
Scope of the Report
The report presents the analysis of Gene and Cell Therapy market for the historical period 2016-2020 and forecast period of 2021-2026.
The report analyses the Gene and Cell Therapy Market by value (USD Million).
The report analyses the Gene and Cell Therapy Market by Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus and Others).
The report analyses the Gene and Cell Therapy Market Application (Oncology, Neurological disorders, cardiovascular disorders, Others).
The Global Gene and Cell Therapy Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA), By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India and South Korea).
The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Vector, By Application.
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include F. Hoffman-La Roche Ltd., Novartis, Sanofi, Alnylam Pharmaceuticals Inc., Pfizer, BlueBird Inc., Sarepta Therapeutics, Voyager Therapeutics, Orchard Therapeutics Plc, AnGes Inc.
Key Target Audience
Biotechnology Companies
Pharmaceutical and Health Companies
Consulting and Advisory Firms
Government and Policy Makers
Regulatory Authorities
The Global Gene and Cell Therapy (GCT) Market is estimated at USD 2504.2 Million in the year 2020. Growth in the historic period in the cell and gene therapy market resulted from increase in investments in cell and gene therapies, growth in research and development, advances in cancer drug discovery, rise in public-private partnerships, strong economic growth in emerging markets, increased healthcare expenditure, and rising in pharmaceutical R&D expenditure.
Companies in the gene and cell therapy for oncology market are increasing their product innovation through strategic collaborations. To sustain in the increasingly competitive market, organizations are developing innovative products as well as sharing skills and expertise with other such enterprises. While oncology drug companies have long collaborated with each other as well as with academic and research institutions in this market by way of partnerships, in or out licensing deals, this trend has been increasing over the recent years.
Further, the market was restrained by inadequate reimbursements, challenges due to regulatory changes, low healthcare access, and limited number of treatment centers. Going forward, increasing prevalence of cancer and chronic diseases, rising geriatric population, rising focus on cell and gene therapy, and rise in healthcare expenditure will drive the growth in the gene and cell therapy market. Factors that could hinder the growth of the market in the future include high costs of therapy, stringent regulations, reimbursement challenges, and coronavirus pandemic.
Scope of the Report
The report presents the analysis of Gene and Cell Therapy market for the historical period 2016-2020 and forecast period of 2021-2026.
The report analyses the Gene and Cell Therapy Market by value (USD Million).
The report analyses the Gene and Cell Therapy Market by Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus and Others).
The report analyses the Gene and Cell Therapy Market Application (Oncology, Neurological disorders, cardiovascular disorders, Others).
The Global Gene and Cell Therapy Market has been analysed By Region (North America, Europe, Asia Pacific, LAMEA), By Country (United States, Canada, Germany, U.K, France, Italy, China, Japan, India and South Korea).
The key insights of the report have been presented through the frameworks of the attractiveness of the market has been presented by region, by Vector, By Application.
Also, the major opportunities, trends, drivers and challenges of the industry has been analysed in the report.
The report tracks competitive developments, strategies, mergers and acquisitions and new product development. The companies analysed in the report include F. Hoffman-La Roche Ltd., Novartis, Sanofi, Alnylam Pharmaceuticals Inc., Pfizer, BlueBird Inc., Sarepta Therapeutics, Voyager Therapeutics, Orchard Therapeutics Plc, AnGes Inc.
Key Target Audience
Biotechnology Companies
Pharmaceutical and Health Companies
Consulting and Advisory Firms
Government and Policy Makers
Regulatory Authorities
TABLE OF CONTENTS
1. Report Scope and Methodology
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Gene and Cell Therapy Market: Product Outlook
4. Global Gene and Cell Therapy Market: Sizing and Forecast
4.1 Global Gene and Cell Therapy Market Size, By Value, Year 2016-2026
5. Global Gene and Cell Therapy Market Segmentation - By Vector, By Application
5.1 Competitive Scenario of Global Gene and Cell Therapy Market: By Vector
5.1.1 Lentivirus - Market Size and Forecast (2016-2026)
5.1.2 AAV - Market Size and Forecast (2016-2026)
5.1.3 Retrovirus & Gammaretrovirus - Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Gene and Cell Therapy Market: By Application
5.2.1 Oncology - Market Size and Forecast (2016-2026)
5.2.2 Neurological Disorders - Market Size and Forecast (2016-2026)
5.2.3 cardiovascular disorders - Market Size and Forecast (2016-2026)
5.2.4 Others - Market Size and Forecast (2016-2026)
6. Global Gene and Cell Therapy Market: Regional Analysis
6.1 Competitive Scenario of Global Gene and Cell Therapy Market : By Region
7. North America Gene and Cell Therapy Market: An Analysis (2016-2026)
7.1 North America Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
7.2 North America Gene and Cell Therapy Market - Prominent Companies
7.3 Market Segmentation By Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others)
7.4 Market Segmentation By Application (Oncology, Neurological Disorders, cardiovascular disorders and Others) 7.5 North America Gene and Cell Therapy Market: Country Analysis
7.6 Market Opportunity Chart of North America Gene and Cell Therapy Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Gene and Cell Therapy Market: By Country
7.8 United States Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
7.9 United States Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
7.10 Canada Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
7.11 Canada Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8. Europe Gene and Cell Therapy Market: An Analysis (2016-2026)
8.1 Europe Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.2 Europe Gene and Cell Therapy Market - Prominent Companies
8.3 Market Segmentation By Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others)
8.4 Market Segmentation By Application (Oncology, Neurological Disorders, cardiovascular disorders and Others)
8.5 Europe Gene and Cell Therapy Market: Country Analysis
8.6 Market Opportunity Chart of Europe Gene and Cell Therapy Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Gene and Cell Therapy Market: By Country
8.8 Germany Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.9 Germany Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8.10 United Kingdom Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8.12 France Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.13 France Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8.14 Italy Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.15 Italy Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9. Asia Pacific Gene and Cell Therapy Market: An Analysis (2016-2026)
9.1 Asia Pacific Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Gene and Cell Therapy Market - Prominent Companies
9.3 Market Segmentation By Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others)
9.4 Market Segmentation By Application (Oncology, Neurological Disorders, cardiovascular disorders, Others)
9.5 Asia Pacific Gene and Cell Therapy Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Gene and Cell Therapy Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Gene and Cell Therapy Market: By Country
9.8 China Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.9 China Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9.10 Japan Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.11 Japan Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.12 India Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9.13 India Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.14 South Korea Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9.15 South Korea Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
10.Global Gene and Cell Therapy Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Gene and Cell Therapy Market - By Vector, 2026
11.2 Market Attractiveness Chart of Global Gene and Cell Therapy Market - Application, 2026
11.3 Market Attractiveness Chart of Global Gene and Cell Therapy Market - By Region, 2026
12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Product Pipeline of Leading Gene Therapy Companies
12.3 Market Share Analysis
13. Company Analysis
13.1 F. Hoffman-La Roche Ltd.
13.2 Novartis
13.3 Sanofi
13.4 Alnylam Pharmaceuticals Inc.
13.5 Pfizer
13.6 BlueBird Inc.
13.7 Sarepta Therapeutics
13.8 Voyager Therapeutics
13.9 Orchard Therapeutics Plc
13.10 AnGes Inc.
Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 6: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 7: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 8: Global Gene and Cell Therapy Market- By Vector Market Share, 2020 & 2026
Figure 9: Global Gene and Cell Therapy Market- By Lentivirus, By Value (USD Million), 2016-2026
Figure 10: Global Gene and Cell Therapy Market- By AAV, By Value (USD Million), 2016-2026
Figure 11: Global Gene and Cell Therapy Market- By Retrovirus & Gammaretrovirus, By Value (USD Million), 2016-2026
Figure 12: Global Gene and Cell Therapy Market- By Others, By Value (USD Million), 2016-2026
Figure 13: Global Gene and Cell Therapy Market- By Application Market Share, 2020 & 2026
Figure 14: Global Gene and Cell Therapy Market- By Oncology, By Value (USD Million), 2016-2026
Figure 15: Global Gene and Cell Therapy Market- By Neurological disorders , By Value (USD Million), 2016-2026
Figure 16: Global Gene and Cell Therapy Market- By cardiovascular disorders, By Value (USD Million), 2016-2026
Figure 17: Global Gene and Cell Therapy Market- By Others, By Value (USD Million), 2016-2026
Figure 18: Global Gene and Cell Therapy Market- By Region Market Share, 2020 & 2026
Figure 19: North America Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 20: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 21: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 22: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 23: North America Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 24: North America Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 25: Market Opportunity Chart of North America Gene and Cell Therapy Market- By Country, By Value (Year-2026)
Figure 26: North America Gene and Cell Therapy Market- By Country Market Share, 2020 & 2026
Figure 27: United States Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 28: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 29: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 30: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 31: United State Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 32: United State Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 33: Canada Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 34: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 35: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 36: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 37: Canada Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 38: Canada Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 39: Europe Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 40: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 41: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 42: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 43: Europe Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 44: Europe Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 45: Market Opportunity Chart of Europe Gene and Cell Therapy Market- By Country, By Value (Year-2026)
Figure 46: Europe Gene and Cell Therapy Market- By Country Market Share, 2020 & 2026
Figure 47: Germany Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 48: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 49: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 50: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 51: Germany Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 52: Germany Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 53: United Kingdom Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 54: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 55: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 56: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 57: United Kingdom Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 58: United Kingdom Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 59: France Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 60: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 61: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 62: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 63: France Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 64: France Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 65: Italy Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Billion)
Figure 66: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 67: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 68: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 69: Italy Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 70: Italy Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 71: Asia Pacific Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 72: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 73: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 74: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 75: Asia Pacific Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 76: Asia Pacific Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 77: Market Opportunity Chart of APAC Gene and Cell Therapy Market- By Country, By Value (Year-2026)
Figure 78: APAC Gene and Cell Therapy Market- By Country Market Share, 2020 & 2026
Figure 79: China Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 80: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 81: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 82: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 83: China Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 84: China Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 85: Japan Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 86: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 87: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 88: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 89: Japan Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 90: Japan Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 91: India Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Figure 92: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 93: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 94: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 95: India Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 96: India Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 97: South Korea Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 98: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 99: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 100: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 101: South Korea Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 102: South Korea Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 103: Market Attractiveness Chart of Global Gene and Cell Therapy Market- By Vector (Year-2026)
Figure 104: Market Attractiveness Chart of Global Gene and Cell Therapy Market- By Application (Year-2026)
Figure 105: Market Attractiveness Chart of Global Gene and Cell Therapy Market- By Region (Year-2026)
Figure 106: Global Gene and Cell Therapy company market share (%), 2020
Figure 107: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 108: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 109: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 110: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 111: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 112: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 113: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 114: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 115: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 116: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 117: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 118: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 119: Alnylam Pharmaceuticals Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 120: Alnylam Pharmaceuticals Inc. sales Revenues, By Business Segment (%), FY2020
Figure 121: Alnylam Pharmaceuticals Inc. sales Revenue, By Geographical Segment (%), FY2020
Figure 122: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 123: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 124: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 125: BlueBird Bio Inc. Sales Revenues, 2015-2019 (USD Million)
Figure 126: Sarepta Therapeutics Sales Revenues, 2015-2019 (USD Million)
Figure 127: Voyager Therapeutics Sales Revenues, 2015-2019 (USD Million)
Figure 128: Orchard Therapeutics PLC Sales Revenues, 2018-2020 (USD Million)
Figure 129: AnGes Inc. Sales Revenues, 2015-2019 (USD Million)
1.1 Scope of the Report
1.2 Research Methodology
1.3 Executive Summary
2. Strategic Recommendations
3. Gene and Cell Therapy Market: Product Outlook
4. Global Gene and Cell Therapy Market: Sizing and Forecast
4.1 Global Gene and Cell Therapy Market Size, By Value, Year 2016-2026
5. Global Gene and Cell Therapy Market Segmentation - By Vector, By Application
5.1 Competitive Scenario of Global Gene and Cell Therapy Market: By Vector
5.1.1 Lentivirus - Market Size and Forecast (2016-2026)
5.1.2 AAV - Market Size and Forecast (2016-2026)
5.1.3 Retrovirus & Gammaretrovirus - Market Size and Forecast (2016-2026)
5.1.4 Others - Market Size and Forecast (2016-2026)
5.2 Competitive Scenario of Global Gene and Cell Therapy Market: By Application
5.2.1 Oncology - Market Size and Forecast (2016-2026)
5.2.2 Neurological Disorders - Market Size and Forecast (2016-2026)
5.2.3 cardiovascular disorders - Market Size and Forecast (2016-2026)
5.2.4 Others - Market Size and Forecast (2016-2026)
6. Global Gene and Cell Therapy Market: Regional Analysis
6.1 Competitive Scenario of Global Gene and Cell Therapy Market : By Region
7. North America Gene and Cell Therapy Market: An Analysis (2016-2026)
7.1 North America Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
7.2 North America Gene and Cell Therapy Market - Prominent Companies
7.3 Market Segmentation By Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others)
7.4 Market Segmentation By Application (Oncology, Neurological Disorders, cardiovascular disorders and Others) 7.5 North America Gene and Cell Therapy Market: Country Analysis
7.6 Market Opportunity Chart of North America Gene and Cell Therapy Market - By Country, By Value, 2026
7.7 Competitive Scenario of North America Gene and Cell Therapy Market: By Country
7.8 United States Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
7.9 United States Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
7.10 Canada Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
7.11 Canada Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8. Europe Gene and Cell Therapy Market: An Analysis (2016-2026)
8.1 Europe Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.2 Europe Gene and Cell Therapy Market - Prominent Companies
8.3 Market Segmentation By Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others)
8.4 Market Segmentation By Application (Oncology, Neurological Disorders, cardiovascular disorders and Others)
8.5 Europe Gene and Cell Therapy Market: Country Analysis
8.6 Market Opportunity Chart of Europe Gene and Cell Therapy Market - By Country, By Value, 2026
8.7 Competitive Scenario of Europe Gene and Cell Therapy Market: By Country
8.8 Germany Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.9 Germany Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8.10 United Kingdom Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.11 United Kingdom Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8.12 France Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.13 France Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
8.14 Italy Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
8.15 Italy Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9. Asia Pacific Gene and Cell Therapy Market: An Analysis (2016-2026)
9.1 Asia Pacific Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.2 Asia Pacific Gene and Cell Therapy Market - Prominent Companies
9.3 Market Segmentation By Vector (Lentivirus, AAV, Retrovirus & Gammaretrovirus, Others)
9.4 Market Segmentation By Application (Oncology, Neurological Disorders, cardiovascular disorders, Others)
9.5 Asia Pacific Gene and Cell Therapy Market: Country Analysis
9.6 Market Opportunity Chart of Asia Pacific Gene and Cell Therapy Market - By Country, By Value, 2026
9.7 Competitive Scenario of Asia Pacific Gene and Cell Therapy Market: By Country
9.8 China Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.9 China Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9.10 Japan Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.11 Japan Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.12 India Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9.13 India Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
9.14 South Korea Gene and Cell Therapy Market Segmentation - By Vector, By Application (2016-2026)
9.15 South Korea Gene and Cell Therapy Market: Size and Forecast (2016-2026), By Value
10.Global Gene and Cell Therapy Market Dynamics
10.1 Drivers
10.2 Restraints
10.3 Trends
11. Market Attractiveness
11.1 Market Attractiveness Chart of Global Gene and Cell Therapy Market - By Vector, 2026
11.2 Market Attractiveness Chart of Global Gene and Cell Therapy Market - Application, 2026
11.3 Market Attractiveness Chart of Global Gene and Cell Therapy Market - By Region, 2026
12. Competitive Landscape
12.1 Major Technological Innovations, Mergers & Acquisitions and Role of Manufacturers
12.2 Product Pipeline of Leading Gene Therapy Companies
12.3 Market Share Analysis
13. Company Analysis
13.1 F. Hoffman-La Roche Ltd.
13.2 Novartis
13.3 Sanofi
13.4 Alnylam Pharmaceuticals Inc.
13.5 Pfizer
13.6 BlueBird Inc.
13.7 Sarepta Therapeutics
13.8 Voyager Therapeutics
13.9 Orchard Therapeutics Plc
13.10 AnGes Inc.
List Of Tables
Figure 1: Global Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)Figure 2: Global Current Healthcare Expenditure Per Capita, 2015-018 (In Numbers)
Figure 3: Global Current Healthcare Expenditure as % of GDP, 2015-2018 (In %)
Figure 4: Global Domestic Private Health Expenditure as % of Current Health Expenditure, 2015-2018 (In %)
Figure 5: Global Prevalence of Neurological Disorders, 2015-2019 (In Billions)
Figure 6: Global Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 7: Global Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 8: Global Gene and Cell Therapy Market- By Vector Market Share, 2020 & 2026
Figure 9: Global Gene and Cell Therapy Market- By Lentivirus, By Value (USD Million), 2016-2026
Figure 10: Global Gene and Cell Therapy Market- By AAV, By Value (USD Million), 2016-2026
Figure 11: Global Gene and Cell Therapy Market- By Retrovirus & Gammaretrovirus, By Value (USD Million), 2016-2026
Figure 12: Global Gene and Cell Therapy Market- By Others, By Value (USD Million), 2016-2026
Figure 13: Global Gene and Cell Therapy Market- By Application Market Share, 2020 & 2026
Figure 14: Global Gene and Cell Therapy Market- By Oncology, By Value (USD Million), 2016-2026
Figure 15: Global Gene and Cell Therapy Market- By Neurological disorders , By Value (USD Million), 2016-2026
Figure 16: Global Gene and Cell Therapy Market- By cardiovascular disorders, By Value (USD Million), 2016-2026
Figure 17: Global Gene and Cell Therapy Market- By Others, By Value (USD Million), 2016-2026
Figure 18: Global Gene and Cell Therapy Market- By Region Market Share, 2020 & 2026
Figure 19: North America Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 20: North America Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 21: North America Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 22: North America Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 23: North America Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 24: North America Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 25: Market Opportunity Chart of North America Gene and Cell Therapy Market- By Country, By Value (Year-2026)
Figure 26: North America Gene and Cell Therapy Market- By Country Market Share, 2020 & 2026
Figure 27: United States Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 28: United State Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 29: United State Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 30: United State Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 31: United State Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 32: United State Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 33: Canada Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 34: Canada Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 35: Canada Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 36: Canada Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 37: Canada Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 38: Canada Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 39: Europe Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 40: Europe Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 41: Europe Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 42: Europe Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 43: Europe Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 44: Europe Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 45: Market Opportunity Chart of Europe Gene and Cell Therapy Market- By Country, By Value (Year-2026)
Figure 46: Europe Gene and Cell Therapy Market- By Country Market Share, 2020 & 2026
Figure 47: Germany Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 48: Germany Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 49: Germany Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 50: Germany Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 51: Germany Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 52: Germany Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 53: United Kingdom Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 54: United Kingdom Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 55: United Kingdom Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 56: United Kingdom Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 57: United Kingdom Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 58: United Kingdom Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 59: France Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 60: France Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 61: France Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 62: France Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 63: France Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 64: France Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 65: Italy Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Billion)
Figure 66: Italy Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 67: Italy Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 68: Italy Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 69: Italy Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 70: Italy Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 71: Asia Pacific Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 72: Asia Pacific Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 73: Asia Pacific Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 74: Asia Pacific Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 75: Asia Pacific Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 76: Asia Pacific Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 77: Market Opportunity Chart of APAC Gene and Cell Therapy Market- By Country, By Value (Year-2026)
Figure 78: APAC Gene and Cell Therapy Market- By Country Market Share, 2020 & 2026
Figure 79: China Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 80: China Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 81: China Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 82: China Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 83: China Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 84: China Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 85: Japan Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 86: Japan Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 87: Japan Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 88: Japan Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 89: Japan Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 90: Japan Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 91: India Pharmacy Retail Market Size, By Value, 2016-2026 (USD Billion)
Figure 92: India Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 93: India Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 94: India Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 95: India Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 96: India Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 97: South Korea Gene and Cell Therapy Market Size, By Value, 2016-2026 (USD Million)
Figure 98: South Korea Prevalence of Neurological Disorders, 2015-2019 (In Millions)
Figure 99: South Korea Prevalence of Cardiovascular Diseases, 2015-2019 (In Millions)
Figure 100: South Korea Prevalence of Total Cancer, 2015-2019 (In Millions)
Figure 101: South Korea Gene and Cell Therapy Market- By Vector, By Value (USD Million), 2016-2026
Figure 102: South Korea Gene and Cell Therapy Market- By Application, By Value (USD Million), 2016-2026
Figure 103: Market Attractiveness Chart of Global Gene and Cell Therapy Market- By Vector (Year-2026)
Figure 104: Market Attractiveness Chart of Global Gene and Cell Therapy Market- By Application (Year-2026)
Figure 105: Market Attractiveness Chart of Global Gene and Cell Therapy Market- By Region (Year-2026)
Figure 106: Global Gene and Cell Therapy company market share (%), 2020
Figure 107: F. Hoffman-La Roche Ltd. Sales Revenues, 2016-2020 (USD Million)
Figure 108: F. Hoffman-La Roche Ltd. Net Income, 2016-2020 (USD Million)
Figure 109: F. Hoffman-La Roche Ltd. sales Revenues, By Business Segment (%), FY2020
Figure 110: F. Hoffman-La Roche Ltd. sales Revenue, By Geographical Segment (%), FY2020
Figure 111: Novartis Annual Sales Revenue (USD Million), 2016-2020
Figure 112: Novartis Annual Net Income/Loss (USD Million), 2016-2020
Figure 113: Novartis Sales Revenue Split, By Business Segment (USD Million), FY2020
Figure 114: Novartis Sales Revenue Split, By Geography Segment (%), FY2020
Figure 115: Sanofi Sales Revenues, 2016-2020 (USD Million)
Figure 116: Sanofi Gross Profit, 2016-2020 (USD Million)
Figure 117: Sanofi Sales Revenue Split, By Business Segment (%), FY2020
Figure 118: Sanofi Sales Revenue Split, By Geography Segment (%), FY2020
Figure 119: Alnylam Pharmaceuticals Inc. Sales Revenues, 2016-2020 (USD Million)
Figure 120: Alnylam Pharmaceuticals Inc. sales Revenues, By Business Segment (%), FY2020
Figure 121: Alnylam Pharmaceuticals Inc. sales Revenue, By Geographical Segment (%), FY2020
Figure 122: Pfizer Annual Sales Revenue (USD Million), 2016-2020
Figure 123: Pfizer Annual Net Income/Loss (USD Million), 2016-2020
Figure 124: Pfizer sales Revenue, By Geographical Segment (%), FY2020
Figure 125: BlueBird Bio Inc. Sales Revenues, 2015-2019 (USD Million)
Figure 126: Sarepta Therapeutics Sales Revenues, 2015-2019 (USD Million)
Figure 127: Voyager Therapeutics Sales Revenues, 2015-2019 (USD Million)
Figure 128: Orchard Therapeutics PLC Sales Revenues, 2018-2020 (USD Million)
Figure 129: AnGes Inc. Sales Revenues, 2015-2019 (USD Million)
RELATED REPORTS
Global Whole Exome Sequencing Market 2023
DescriptionThe Whole Exome Sequencing Market is poised for substantial growth, with a projected increase from USD 1.43 billion in 2022 to USD 3.75 billion by 2029. This growth is expected
View ReportGlobal Continuous Bioprocessing Market 2023
DescriptionThe global Continuous Bioprocessing Market size is anticipated to expand from USD 133.9 million in 2022 to USD 443.1 million by 2029, registering a compound annual growth rate (CAGR) of
View ReportGlobal Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market Growth Opportunities in the US, Europe, Japan
Global Genetic Diseases, Cancer, Forensic and Paternity Molecular Diagnostics Market Growth Opportunities in the US, Europe, JapanThe report is available by section, market segment, and can be customized to your
View ReportGlobal Generic Drugs Market 2023-2029
According to the latest data, the market size of the global generic drugs sector is expected to rise by USD 226.3 billion with a CAGR of 7.2% by the end
View ReportSAMPLE REQUEST
Fill The Form For Sample Request
REVIEWS
